Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. - Moricke,A.; Reiter,A.; Zimmermann,M.; Gadner,H.; Stanulla,M.; Dordelmann,M. (Blood, 2008)